CluenexGilead Sciences Inc GILD
Gilead Sciences Inc scores average on business quality (6.0 of 10). Here is why, in plain words, and what our sealed record shows.
Why it matters
- What Gilead Sciences Inc does
Gilead Sciences sells antiviral drugs and therapeutics, primarily generating revenue from treatments targeting HIV, viral hepatitis, and oncology. Hospitals, clinics, and government health programs pay for these therapies to manage chronic and life-threatening conditions. The company is currently expanding its oncology pipeline and clinical trials to offset legacy revenue pressures.
- What it does best
Gilead dominates the HIV treatment market through entrenched physician relationships and high switching costs. Its gross margin hits 79.6 percent, sitting in the top quartile of its sector and outperforming peers like AbbVie at 72.7 percent.
- The main risk
Pipeline execution risks threaten future growth, as shown by mounting competitive pressure on partners like Legend Biotech ahead of critical regulatory decisions.
Quality, check by check
Scored against its own industry, from company filings.
Operating margins reach 38.6 percent with free cash flow margins in the 96th sector percentile, expanding as high-margin therapies scale efficiently.
Patented drug portfolios and high patient adherence create strong switching costs that lock in chronic users. Its operating margin sits in the 94th sector percentile, backed by defensible IP.
Revenue grew 2.4 percent to $30.5B, ranking in the bottom quartile of its sector at the 20th percentile and demonstrating sluggish top-line momentum.
Total debt sits at $24.9B against $7.6B in cash, while interest coverage of 11.8x makes debt servicing manageable. Free cash flow reaches $12.7B, showing a softer balance sheet.
Insiders
Executives and directors, from SEC Form 4 filings we read ourselves. Open market trades only; grants, option exercises and pre-planned sales left out.
No open market buys or unplanned sales by executives or directors.
Our sealed record on GILD
Verdicts appear here 30 days after we publish them; members see today's. Each one is in the nightly ledger, fingerprinted the night it was made.
The first sealed verdicts appear here on Oct 11, 2026.
Questions
Gilead Sciences Inc scores average on the Cluenex quality check (6.0 of 10), measured against its own industry. Profitability is strong, moat strong, growth slow and financial health fair.
In the last 90 days of SEC Form 4 filings: No open market buys or unplanned sales by executives or directors.
Oct 22, 2026.
See GILD today
- Today's verdict on GILD, and why
- Fair value with cautious, base and optimistic cases
- The exact price that would change the verdict
- Which stocks each signal names, the night it fires
Cite this page: Cluenex, “Gilead Sciences Inc (GILD)”, https://cluenex.com/stocks/gild/, data as of Oct 10, 2026.